September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Results of Cataract Surgery in Cancer Patients Receiving Chemotherapy
Author Affiliations & Notes
  • Amelia Fong
    Ophthalmology, Georgetown/Washington Hospital Center, Washington DC, District of Columbia, United States
  • Aruoriwo Oboh-Weilke
    Ophthalmology, Georgetown/Washington Hospital Center, Washington DC, District of Columbia, United States
  • Footnotes
    Commercial Relationships   Amelia Fong, None; Aruoriwo Oboh-Weilke, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amelia Fong, Aruoriwo Oboh-Weilke; Results of Cataract Surgery in Cancer Patients Receiving Chemotherapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The outcome of elective cataract surgery of patients undergoing chemotherapy has not been investigated. The limited amount of literature suggests that chemotherapy patients have a higher rate of surgical complications versus cancer patients who undergo primary surgery. However, there is no significant difference in negative outcomes between immunocompromised versus immunocompetent patients undergoing elective surgery. Our purpose was to investigate if chemotherapy patients may safely undergo elective cataract surgery.

Methods : A retrospective chart review of patients with cancer who underwent cataract extraction by a single provider. Inclusion criteria was patients with a known diagnosis of cancer currently undergoing chemotherapy or who had recently received chemotherapy prior to surgery. Exclusion criteria was non-compliance with drops or visits, follow-up time of less than 1 month, and ocular metastasis. Outcome measures were any adverse events during surgery or in the post-operative period.

Results : Six patients with eight eyes were identified ranging in age from 53 to 73 years old. Five cancer diagnoses were represented (breast, multiple myeloma, ovarian, liver and prostate cancer), and all patients were either between their chemotherapy cycles, or had finished receiving their chemotherapy prior to surgery. All patients had uneventful cataract surgery with no complications. There were no adverse events reported (e.g. posterior capsule tear, loss of vitreous, high IOP, delayed wound healing, infection). The post-operative period was unremarkable with no prolonged inflammation or increased use of drops. All patients had an improvement in vision after cataract surgery.

Conclusions : Visual impairment due to cataracts bears significant quality of life implications for anyone, including cancer patients. Chemotherapy courses often extend over many months. Our study results suggest that surgery can be safely performed concurrent with chemotherapy. The quality of life benefits of surgical treatment of cataracts should not be withheld based on chemotherapy status alone.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×